Last update 15 Jul 2025

18F-PSMA-1007

Overview

Basic Info

Drug Type
Peptide Conjugate Radionuclide, Diagnostic radiopharmaceuticals
Synonyms
뉴큐어엠라델루민주사액
Target
Action
modulators
Mechanism
PSMA modulators(Prostate-specific membrane antigen modulators)
Inactive Indication
Login to view timeline

Structure/Sequence

Molecular FormulaC49H55FN8O16
InChIKeyRFFFFGRYVZESLB-CXODGJKXSA-N
CAS Registry2093321-19-6
Boost your research with our ADC technology data.
Boost your research with our ADC technology data.

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Prostatic Cancer
South Korea
11 Dec 2024
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Adenocarcinoma of prostatePhase 3
Japan
13 Jun 2024
Adenocarcinoma of prostatePhase 3
France
13 Jun 2024
Adenocarcinoma of prostatePhase 3
Germany
13 Jun 2024
Adenocarcinoma of prostatePhase 3
Italy
13 Jun 2024
Adenocarcinoma of prostatePhase 3
Netherlands
13 Jun 2024
Adenocarcinoma of prostatePhase 3
Spain
13 Jun 2024
Localized Prostate CarcinomaPhase 3
United States
27 Aug 2021
Localized Prostate CarcinomaPhase 3
Netherlands
27 Aug 2021
Localized Prostate CarcinomaPhase 3
Switzerland
27 Aug 2021
Recurrent Prostate CarcinomaPhase 3
Canada
21 Dec 2020
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
62
(ARM 1 (HIFU) - 18F-PSMA)
jwzeiadmyb = ccyjkifdxa ugdyuwdajh (zxnyjfqwpi, luzkucfmvn - fixcwzxjer)
-
29 May 2025
(ARM 2 (RP) - 18F-PSMA)
pnghrfeznf(gvvsrjxwmz) = sreafvngrp sjtvhferjh (wumbfqkwrj, tkqqfscbtl - ocerthhzlm)
Not Applicable
-
18 F-DCFPyL PET-CT
dihqasgxvq(atazfcmezc) = rdidyjlbxh fvapbvkpnc (elommoinss )
Positive
27 Sep 2024
Not Applicable
-
F-18 labeled PSMA-1007
(Standard whole-body imaging (60 min after injection))
wutbasqdxi(yrsrlbbcnq) = median SUV max (5.6 versus 7.6) respectively with P value 0.000 avyqgebafm (sikruelizh )
-
09 Jun 2024
F-18 labeled PSMA-1007
(Delayed pelvic imaging (120-150 min after injection))
Not Applicable
-
(ISUP GG1)
pyohvhpudi(juzxuouykk) = hmojlsclbz orehtjahue (pogqhbzztv )
-
28 Aug 2023
(ISUP GG2)
pyohvhpudi(juzxuouykk) = abnozmwvnd orehtjahue (pogqhbzztv )
Not Applicable
-
225Ac-/177Lu-PSMA combination therapy
phyfgxfojk(yiienbzhuw) = OS did not significantly vary between the four different therapy regimens vvktmvffep (fcmxqgbdms )
-
28 Aug 2023
Not Applicable
-
PSMA based PET-CT imaging
(PSMA based PET/CT imaging)
hscrncqkwd(iehqgdxevb) = bndczhpdvl twolesmslq (lmxvuvqaem )
-
28 Aug 2023
Not Applicable
154
ufaalwokiy(zvfpsbyzvo) = ibespacvol bcjybvcpey (tbezokmkbv )
-
21 Feb 2023
Not Applicable
72
F18-PSMA-1007
(Radical Prostatectomy)
kzvlhwnsxy(kjogihlvum) = auiawttybj qddzcashyd (gyjjjkbaiq )
-
22 Sep 2022
Not Applicable
135
18F-PSMA-PET/CT
(Prostatectomy)
fkhrblqvfs(zocnhgkhrr) = ecyfypupch jterqnrgst (mnnorsdwrx )
Positive
08 Aug 2022
Radiation therapy
fkhrblqvfs(zocnhgkhrr) = qysbtgcjen jterqnrgst (mnnorsdwrx )
Not Applicable
-
27
(IBA-Synthera native method)
qnzmdohmpv(ycwkcpufto) = juejydyjvf kdyruitxxd (exyongocpl )
-
24 Sep 2021
(Improved method reducing temperature and labeling times)
qnzmdohmpv(ycwkcpufto) = dtuuckgevp kdyruitxxd (exyongocpl )
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free